KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $251.5 million.

  • Jazz Pharmaceuticals' Net Income towards Common Stockholders rose 16.77% to $251.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.9 million, marking a year-over-year increase of 21.63%. This contributed to the annual value of $561.8 million for FY2024, which is 34.45% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Net Income towards Common Stockholders of $251.5 million as of Q3 2025, which was up 373.29% from -$92.0 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at $251.5 million during Q3 2025, with a 5-year trough of -$364.7 million in Q2 2021.
  • In the last 3 years, Jazz Pharmaceuticals' Net Income towards Common Stockholders had a median value of $126.4 million in 2023 and averaged $113.9 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first slumped by 641.83% in 2022, then spiked by 1,116.53% in 2023.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Net Income towards Common Stockholders stood at -$32.3 million in 2021, then slumped by 641.83% to -$240.0 million in 2022, then soared by 139.43% to $94.6 million in 2023, then skyrocketed by 102.01% to $191.1 million in 2024, then rose by 16.77% to $251.5 million in 2025.
  • Its last three reported values are $251.5 million in Q3 2025, -$92.0 million for Q2 2025, and $191.1 million during Q4 2024.